Cost-effectiveness of a psychoeducational relapse prevention program for depression in primary care

Journal of Mental Health Policy and Economics

Volumn 12, Issue 4, 2009, Pages

  Stant, A Dennis ^a   Ten Vergert, Elisabeth M ^a   Kluiter, Herman ^a   Conradi, Henk Jan ^a   Smit, Annet ^a,b   Ormel, Johan ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Gelderse Roos Institute for Professionalization Research   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; COGNITIVE THERAPY; CONSULTATION; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DEPRESSION; FEMALE; FOLLOW UP; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL HEALTH CARE; MENTAL HEALTH SERVICE; OUTCOME ASSESSMENT; PRIMARY MEDICAL CARE; PRODUCTIVITY; PSYCHOEDUCATION; QUALITY ADJUSTED LIFE YEAR;

ANTIDEPRESSIVE AGENTS; COST-BENEFIT ANALYSIS; DEPRESSIVE DISORDER, MAJOR; HUMANS; PATIENT EDUCATION AS TOPIC; PRIMARY HEALTH CARE; PSYCHIATRY; QUALITY-ADJUSTED LIFE YEARS; RECURRENCE; SELF CARE; SELF EFFICACY;

EID: 75749108540     PISSN: 10914358     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Üstün TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJL. Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004; 184: 386-392.
2. Wells KB, Stewart A, Hays RD, Burnam MA, Rogers W, Daniels M, Berry S, Greenfield S, Ware J. The functioning and well-being of depressed patients. Results from the Medical Outcome Study. JAMA 1989; 262: 914-919.
3. Ormel J, VonKorff M, Ustun TB, Pini S, Korten A, Oldehinkel T. Common mental disorders and disability across cultures. Results from the WHO Collaborative Primary Care Study. JAMA 1994; 272: 1741-1748.
4. Ormel J, Oldehinkel AJ, Nolen WA, Vollebergh W. Psychosocial disability before, during, and after a major depressive episode: a 3wave populationbased study of state, scar, and trait effects. Arch Gen Psychiatry 2004; 6: 387-392.
5. Polder JJ, Takkern J, Meerding WJ, Kommer GJ, Stokx LJ. Cost of illness in the Netherlands. Bilthoven: RlVM, 2002.
6. Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, Corey-Lisle PK. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003; 64: 1465-1475.
7. Berto P, D'Ilario D, Ruffo P, Di Virgilio R, Rizzo F. Depression: Cost-of-illness Studies in the International Literature, a Review. J Ment Health Policy Econ 2000; 3: 3-10.
8. Barrett B, Byford S, Knapp M. Evidence of cost-effective treatments for depression: a systematic review. J Affect Disord 2005; 84: 1-13.
9. Bosmans JE. Cost-effectiveness of treatment of depression in primary care. Thesis. Enschede: Febodruk, 2006.
10. Mc Intyre RS, O' Donovan C. The human cost of not achieving full remission in depression. Can J Psychiatry 2004; 49: 10-16.
11. Katon W, Ludman E, Simon G, et al. Depression: self-care companion for better living (book and video). Seattle: Time Life Medical, 1996.
12. Tiemens BG, Jenner JA, Kluiter H, Van der Meer K. Trek je eigen plan: een wegwijzer voor zelfzorg bij depressie (book and video). Groningen: Rijksuniversiteit Groningen, 1998.
13. Ludman E, Von Korff M, Katon W, Lin E, Simon G, Walker E, Unützer J, Bush T, Wahab S. The design, implementation and acceptance of a primary care-based intervention to prevent depression relapse. Int J Psychiatry Med 2000; 30: 229-245.
14. Smit A, Kluiter H, Conradi HJ, van der Meer K, Tiemens BG, Jenner JA, van Os TW, Ormel J. Enhanced treatment for depression in primary care: first year results on compliance, self-efficacy, the use of antidepressants and contacts with the primary care physician. Prim Care Community Psychiatry 2005; 10: 39-49.
15. Simon GE, Von Korff M, Ludman EJ, Katon WJ, Rutter C, Unützer J, Lin EH, Bush T, Walker E. Cost-effectiveness of a program to prevent depression relapse in primary care. Med Care 2002; 40: 941-950.
16. Smit A, Kluiter H, Conradi HJ, van der Meer K, Tiemens BG, Jenner JA, van Os TW, Ormel J. Short-term effects of enhanced treatment for depression in primary care: Results from a randomised controlled trial. Psychol Med 2006; 36: 15-26.
17. Conradi HJ, de Jonge P, Kluiter H, Smit A, van der Meer K, Jenner JA, van Os TW, Emmelkamp PM, Ormel J. Enhanced treatment for depression in primary care: long-term outcomes of a psycho-educational prevention program alone and enriched with psychiatric consultation or cognitive behavioral therapy. Psychol Med 2007; 37: 849-62.
18. Boelens W. Procolised treatment of depressive disorders: cognitive behavioral therapy (in Dutch). In Keijsers GPJ, Van Minnen A, Hoogduin CAL(Eds). Protocollaire behandelingen in de ambulante GGZ. Houten: Bonn, Stafleu, Van Loghum, 1997. p. 15-42.
19. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, Rush AJ, Weissman MM. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991; 48: 851-855.
20. Koopmanschap MA, Rutten FFH, Van Ineveld BM, Van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ 1995; 14: 171-189.
21. Jakob-Tacken KHM, Koopmanschap MA, Meerding WJ, Severens JL. Correcting for compensating mechanisms related to productivity costs in economic evaluations of healthcare programmes. J Health Econ 2005; 14: 435-443.
22. Oostenbrink JB, Koopmanschap MA, Rutten FFH. Manual for cost studies, methods and standard prices for economic evaluation in healthcare (In Dutch). Amstelveen: Healthcare Insurance Council, 2000.
23. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. Methods for the economic evaluation of Healthcare Programmes. Oxford: Oxford University Press, 1997.
24. Schwappach DL. Resource allocation, social values and the QALY: a review of the debate and empirical evidence. Health Expect 2002; 5: 210-222.
25. EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
26. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35: 1095-1108.
27. Efron B, Tibshirani RJ. An introduction to the bootstrap. New York: Chapman & Hall, 1993.
28. Black WC. The CE plane: a graphic representation of cost-effectiveness. Med Decis Making 1990; 10: 212-214.
29. Van Hout BA, Al MJ, Gordon GS, Rutten FFH. Costs, effects and C/E ratios alongside a clinical trial. Health Econ 1994; 3: 309-19.
30. Fenwick E, O'Brien BJ, Briggs A. Cost-effectiveness acceptability curves - facts, fallacies and frequently asked questions. Health Econ 2004; 13: 405-415.
31. Little RJA, Rubin DB. Statistical analysis with missing data. New York: John Wiley and Sons, 1987.
32. Briggs A, Clark T, Wolstenholme J, Clarke P. Missing...presumed at random: cost-analysis of incomplete data. Health Econ 2003; 12: 377-392.
33. Oostenbrink JB, Al MJ. The analysis of incomplete cost data due to dropout. Health Econ 2005; 14: 763-76.
34. Scott J, Palmer S, Paykel E, Teasdale J, Hayhurst H. Use of cognitive therapy for relapse prevention in chronic depression. Br J Psychiatry 2003; 182: 221-227.
35. Lave JR, Frank RG, Schulberg HC, Kamlet MS. Cost-effectiveness of treatments for major depression in primary care practice. Arch Gen Psychiatry 1998; 55: 645-51.
36. Hollon SD, DeRubeis RJ, Shelton RC, Amsterdam JD, Salomon RM, O'Reardon JP, Lovett ML, Young PR, Haman KL, Freeman BB, Gallop R. Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Arch Gen Psychiatry 2005; 62: 417-422.
37. Revicki DA, Siddique J, Frank L, Chung JY, Green BL, Krupnick J, Prasad M, Miranda J. Cost-effectiveness of evidence-based pharmacotherapy or cognitive behavior therapy compared with community referral for major depression in predominantly low-income minority women. Arch Gen Psychiatry 2005; 62: 868-875.
38. Vos T, Corry J, Haby MM, Carter R, Andrews G. Cost-effectiveness of cognitive-behavioural therapy and drug interventions for major depression. Aust N Z J Psychiatry 2005; 39: 683-92.
39. McCrone P, Knapp M, Proudfoot J, Ryden C, Cavanagh K, Shapiro DA, Ilson S, Gray JA, Goldberg D, Mann A, Marks I, Everitt B, Tylee A. Cost-effectiveness of computerised cognitive-behavioural therapy for anxiety and depression in primary care: randomised controlled trial. Br J Psychiatry 2004; 185: 55-62.
40. Mauskopf J, Rutten F, Schonfeld W. Cost-effectiveness league tables: valuable guidance for decision makers? Pharmacoeconomics 2003; 21: 991-1000.
41. Donald-Sherbourne C, Unützer J, Schoenbaum M, Duan N, Lenert LA, Sturm R, Wells KB. Can utility-weighted health-related quality-of-life estimates capture health effects of quality improvement for depression? Med Care 2001; 39: 1246-1259.
42. Sapin C, Fantino B, Nowicki ML, Kind P. Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder. Health Qual Life Outcomes 2004; 5: 2-20.